SCHEDULE: State Street Discloses 5.4% Stake in Sarepta Therapeutics

State Street Corporation has reported a 5.4% beneficial ownership stake in Sarepta Therapeutics Inc., holding over 5.3 million common shares.

Summary

• State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Sarepta Therapeutics Inc.
• As of September 30, 2025, State Street Corporation beneficially owns 5,304,907 shares of Sarepta Therapeutics' common stock.
• This ownership represents 5.4% of the total class of securities.
• State Street Corporation holds shared voting power over 5,055,825 shares.
• State Street Corporation holds shared dispositive power over 5,304,907 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing itself is a factual disclosure of ownership, which is neutral. However, a large institutional investor like State Street taking a significant stake is generally viewed as a positive signal for the issuer, suggesting confidence in its value or future prospects.

Positives

• A significant institutional investor like State Street Corporation taking a 5.4% stake can signal confidence in Sarepta Therapeutics' long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic, rather than activist, investment approach.

Negatives

• NA

Risks

• NA

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Sarepta Therapeutics or State Street Corporation regarding the issuer's future performance.

Industry Context

Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating a passive investment intent. State Street Corporation, as a major asset manager, frequently files such reports as part of its investment activities across various sectors, including biotechnology, where Sarepta Therapeutics operates.

Stakeholder Impact

• Shareholders: May view State Street's significant stake as a vote of confidence, potentially leading to increased investor interest or stability in the stock.
• Company Management: The presence of a large institutional investor like State Street may influence corporate governance discussions, though the filing indicates a passive investment intent.

Key Dates

Keywords

State Street Corporation, Sarepta Therapeutics, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Equity Stake